111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.

111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.

Show other versions (2)

INTRODUCTION: The F3 peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK), a fragment of the human high mobility group protein 2, binds nucleolin. Nucleolin is expressed in the nuclei of normal cells but is also expressed on the membrane of some cancer cells. The goal was to investigate the use of 111In-labele...

Full description

Bibliographic Details
Main Authors:	Cornelissen, B, Waller, A, Target, C, Kersemans, V, Smart, S, Vallis, K
Format:	Journal article
Language:	English
Published:	SpringerOpen 2012

Similar Items

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
by: Cornelissen, B, et al.
Published: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
by: Cornelissen, B, et al.
Published: (2012)

Auger electron therapy using In-111-labelled F3 peptide
by: Cornelissen, B, et al.
Published: (2011)

Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
by: Reilly, R, et al.
Published: (2006)

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
by: Costantini, D, et al.
Published: (2008)

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
by: Costantini, D, et al.
Published: (2010)

Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer
by: Conrad Chan, et al.
Published: (2022-12-01)

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
by: Costantini, D, et al.
Published: (2007)

ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
by: Cornelissen, B, et al.
Published: (2011)

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
by: Bailey, K, et al.
Published: (2007)

Targeting the nucleus: an overview of Auger-electron radionuclide therapy.
by: Cornelissen, B, et al.
Published: (2010)

Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and gamma-radiation on EGFR-positive breast cancer cells.
by: Chen, P, et al.
Published: (2002)

A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
by: Reilly, R, et al.
Published: (2004)

The anti-tumor effect of the auger electron-emitting radiopharmaceutical, In-111-hEGF against MDA-MB-468 human breast cancer xenografts is tumor-size dependent.
by: Chen, P, et al.
Published: (2001)

Radiosynthesis and Animal Studies of 111In-DTPA-bis-alendronate Complex
by: Ashraf Fakhari, et al.
Published: (2015-09-01)

Single cell S-value calculations of a stochastic cascade model for Auger-electron emitting radionuclides
by: Vallis, K, et al.
Published: (2016)

Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
by: Cai, Z, et al.
Published: (2008)

Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
by: Hu, M, et al.
Published: (2007)

Internalization of Auger electron-emitting isotopes into cancer cells: A method for spatial distribution determination of equivalent source terms
by: Vallis, K, et al.
Published: (2016)

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu
by: Sadaf Aghevlian, et al.
Published: (2020-11-01)

Integrin Targeted Delivery of Radiotherapeutics
by: Zhaofei Liu, Fan Wang, Xiaoyuan Chen
Published: (2011-01-01)

Regulatory T cells in radiotherapeutic responses
by: Dörthe eSchaue, et al.
Published: (2012-08-01)

Absorbed dose evaluation of auger electron-emitting radionuclides: impact of input decay spectra on dose point kernels and S-values
by: Falzone, N, et al.
Published: (2017)

Synthesis and evaluation of an 18F-labeled derivative of F3 for targeting surface expressed nucleolin in cancer and tumor endothelial cells
by: Vallis, K, et al.
Published: (2016)

Computational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to (111)In-DTPA-hEGF or gamma-rays using Image-J software.
by: Cai, Z, et al.
Published: (2009)

Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.
by: Vallis, K, et al.
Published: (2014)

SPECT imaging and biodistribution studies of 111In-EGF-Au-PEG nanoparticles in vivo
by: Song, L, et al.
Published: (2016)

Targeted Radiotherapeutics from 'Bench-to-Bedside'
by: Cristina Müller, et al.
Published: (2020-12-01)

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
by: McLarty, K, et al.
Published: (2009)

Photoresists as a high spatial resolution autoradiography substrate for quantitative mapping of intra- and sub-cellular distribution of Auger electron emitting radionuclides.
by: Falzone, N, et al.
Published: (2012)

111In-DTPA-Octreotide SPECT (OctreoScan) uptake in metastatic renal cell carcinoma to the pancreas
by: Chan, K, et al.
Published: (2018)

STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy
by: Ping-Lian Yang, et al.
Published: (2020-08-01)

Radiotherapeutic alternatives for previously irradiated recurrent gliomas
by: Schulz-Ertner Daniela, et al.
Published: (2007-08-01)

Augers and auger bits
by: 8096 British Standards Institution

Light-emitting properties of BN synthesized by different techniques
by: G.Yu. Rudko, et al.
Published: (2020-06-01)

The identification and validation of Auger electron-emitting radiopharmaceuticals targeting telomerase for cancer therapy
by: Jackson, M
Published: (2013)

Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy
by: Terry, S, et al.
Published: (2012)

Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy.
by: Terry, S, et al.
Published: (2012)

Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide.
by: Isidori, A, et al.
Published: (2002)

Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.
by: Kaltsas, G, et al.
Published: (1998)